Investigational drug · Phase 3
YK-209A
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC).
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 5, 2023 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "YK-209A"
First trial start
2023
May 1, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "YK-209A", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "YK-209A" as an intervention, largest first.
- YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsPivotal-lookingNot yet recruiting
Suzhou Puhe Pharmaceutical Technology Co., LTDIndustry
NCT05767892 · 350 participants (planned) · Start May 1, 2023 · Primary completion Jul 30, 2025
Drug: YK-209A tablet; Pemetrexed+carboplatin/Cisplatin · For: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Sites: Bengbu, China; Hefei, China; Wuhu, China · 52 sites in all
- Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFRStatus unknown
Suzhou Puhe Pharmaceutical Technology Co., LTDIndustry
NCT05767866 · 160 participants (planned) · Start Mar 30, 2018 · Primary completion Dec 30, 2023
Drug: YK-029A · For: Treatment; Treatment Side Effects
Sites: Hefei, China; Guangzhou, China; Nanjing, China · 35 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.